NovoBiotic Pharmaceuticals LLC
NovoBiotic Pharmaceuticals is a privately held, early stage biotechnology company focused on the discovery and development of new drugs from natural sources. They specialize in discovering new antibiotics targeting serious drug-resistant infections by accessing the >99% of microbes previously believed to be unculturable, thus exploring a virtually unlimited diversity of natural products.
Industries
Nr. of Employees
small (1-50)
NovoBiotic Pharmaceuticals LLC
Products
Teixobactin (antibiotic candidate)
A novel antibiotic class discovered from previously uncultivable microbes; cell wall synthesis inhibitor binding multiple lipid precursors with reported high potency against Gram-positive pathogens and demonstrated preclinical efficacy.
Clovibactin (peptide antibiotic candidate)
A peptide antibiotic discovered via environmental microbial screening; reported potent activity against Gram-positive pathogens, rapid bactericidal activity via cell wall precursor binding, and preclinical efficacy in mouse infection models.
Lassomycin (anti-mycobacterial compound)
A compound that inhibits the mycobacterial Clp protease, active against Mycobacterium tuberculosis including dormant cells; identified from environmental microbial sources.
Teixobactin (antibiotic candidate)
A novel antibiotic class discovered from previously uncultivable microbes; cell wall synthesis inhibitor binding multiple lipid precursors with reported high potency against Gram-positive pathogens and demonstrated preclinical efficacy.
Clovibactin (peptide antibiotic candidate)
A peptide antibiotic discovered via environmental microbial screening; reported potent activity against Gram-positive pathogens, rapid bactericidal activity via cell wall precursor binding, and preclinical efficacy in mouse infection models.
Lassomycin (anti-mycobacterial compound)
A compound that inhibits the mycobacterial Clp protease, active against Mycobacterium tuberculosis including dormant cells; identified from environmental microbial sources.
Services
Isolation and cultivation of previously uncultivable soil and marine microbes, extraction and screening of microbial secondary metabolites for antimicrobial activity, and follow-up hit characterization.
Services to advance antibiotic leads including fermentation/scale-up for material supply, formulation development for parenteral delivery, production of GMP material for clinical trials, and regulatory/CMC planning.
Participation and management of multi-institutional, grant-funded research projects focused on antibiotic and antifungal discovery and development.
Isolation and cultivation of previously uncultivable soil and marine microbes, extraction and screening of microbial secondary metabolites for antimicrobial activity, and follow-up hit characterization.
Services to advance antibiotic leads including fermentation/scale-up for material supply, formulation development for parenteral delivery, production of GMP material for clinical trials, and regulatory/CMC planning.
Participation and management of multi-institutional, grant-funded research projects focused on antibiotic and antifungal discovery and development.
Expertise Areas
- Natural product discovery from environmental microbes
- Antibiotic lead discovery and preclinical development
- Cultivation and domestication of previously uncultivable microorganisms
- Fermentation and bioprocess scale-up for microbial natural products
Key Technologies
- In situ diffusion-chamber cultivation
- Miniaturized isolation devices (iChip-style)
- 16S rDNA taxonomic profiling
- HPLC
News & Updates
Various press releases about the company's research, discoveries, and grants, including the publication of a new article in ACS Infection Diseases about teixobactin, discovery of a new class of antibiotic called clovibactin, and multiple grants from NIH/NIAID and the US Army for developing antibiotics like teixobactin for drug-resistant infections and biothreats.
An article in ACS Infection Diseases showing teixobactin's efficacy in a rabbit model of inhalation anthrax, highlighting its unique mechanism and resistance-free profile.
A major article in the journal Cell reporting on the discovery of a new class of antibiotic, clovibactin, with activity against Gram-positive pathogens, and the dual mechanism of teixobactin.
Discovery of Teixobactin
Discovered by NovoBiotic using proprietary iChip technology, teixobactin is a new class of antibiotic highly potent against Gram-positive bacteria, with a mechanism that minimizes resistance development.
Discovery of Clovibactin (Novo29)
A new antimicrobial compound that inhibits bacterial cell wall synthesis, effective against resistant bacteria like MRSA, and in preclinical development.
Publication in Nature about Teixobactin
The discovery and development of teixobactin was published in Nature, highlighting its potential as a new antibiotic with no detectable resistance.
Various press releases about the company's research, discoveries, and grants, including the publication of a new article in ACS Infection Diseases about teixobactin, discovery of a new class of antibiotic called clovibactin, and multiple grants from NIH/NIAID and the US Army for developing antibiotics like teixobactin for drug-resistant infections and biothreats.
An article in ACS Infection Diseases showing teixobactin's efficacy in a rabbit model of inhalation anthrax, highlighting its unique mechanism and resistance-free profile.
A major article in the journal Cell reporting on the discovery of a new class of antibiotic, clovibactin, with activity against Gram-positive pathogens, and the dual mechanism of teixobactin.
Discovery of Teixobactin
Discovered by NovoBiotic using proprietary iChip technology, teixobactin is a new class of antibiotic highly potent against Gram-positive bacteria, with a mechanism that minimizes resistance development.
Discovery of Clovibactin (Novo29)
A new antimicrobial compound that inhibits bacterial cell wall synthesis, effective against resistant bacteria like MRSA, and in preclinical development.
Publication in Nature about Teixobactin
The discovery and development of teixobactin was published in Nature, highlighting its potential as a new antibiotic with no detectable resistance.